

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 4th September 2025

FOI Ref 30162

Requested Information:

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:•

Adalimumab - Humira

- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Spesolimab

Response:

Adalimumab - Humira	0
Adalimumab	
Biosimilar	192
Apremilast	15
Bimekizumab	2
Brodalumab	9
Certolizumab	6
Deucravacitinib	3
Dimethyl fumarate	0
Etanercept - Enbrel	1
Etanercept Biosimilar	9
Guselkumab	4
Infliximab - Remicade	0
Infliximab Biosimilar	2
Ixekizumab	14
Risankizumab	33
Secukinumab	37
Tildrakizumab	7
Ustekinumab - Stelara	0
Ustekinumab	
Biosimilar	46
Spesolimab	0

Attachment(s):

No attachment(s)

Date Response sent: 5th September 2025